Hosted on MSN1mon
Leerink raises 89bio stock target to $37 on NASH study optimism(NASDAQ:ETNB) to $37 from $34, while reiterating an Outperform ... data from a Phase 2b SYMMETRY study of efruxifermin (EFX) in NASH patients with compensated cirrhosis. The results demonstrated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback